XZXiaoyi Zhang

Xiaoyi Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoyi Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ming Zhao

    Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China; Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, China

    3 shared publications
  • Qiqi Feng

    Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

    3 shared publications
  • Shurui Zhao

    Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

    3 shared publications
  • Yaonan Wang

    School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

    3 shared publications
  • Qi Gao

    Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, People’s Republic of China

    2 shared publications
  • Chengli Wu

    School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China

    1 shared publication

Latest Publications

  • Open Access

    GA-LDV: A Promising Derivative of 18β-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties

    by Jiaying Zheng, Qiqi Feng, Qi Gao, Yaonan Wang, Shurui Zhao, Xiaoyi Zhang, Ming Zhao

    Purpose: The clinical translation of 18β-Glycyrrhetinic acid (GA) is impeded by its relatively low antitumor potency and poor aqueous solubility, we developed a novel derivative of GA by incorporating the Leu-Asp-Val (LDV) tripeptide to enhance its anti-tumor and anti-metastatic activities both in vitro and in vivo, thereby increasing its potential as a therapeutic agent for cancer treatment. Methods: The water solubility of GA-LDV was evaluated. The inhibitory effects of GA-LDV on cell viability were assessed in four different human cancer cell lines. In vitro assays were conducted to measure the compound’s impact on tumor cell adhesion, migration, and invasion. In vivo studies were performed using S180 and LLC xenograft models to evaluate the tumor inhibition and anti-metastatic properties. Results: GA-LDV water solubility was increased 4.1 folds compared with GA. In vitro assays suggested that GA-LDV, at a concentration of 25 μM, significantly impeded the adhesion, migration, and invasion of LLC tumor cell lines, with inhibition rates of 52.7%, 55.5% (vs GA 16.9%, P < 0.05) and 35.9% (vs GA 27.5%, P < 0.05). Moreover, GA-LDV demonstrated stronger tumor inhibition ability than GA (P < 0.05), and anti-metastasis activities in a dose-dependent manner, at the concentration of 5 μmol/kg/d, 1 μmol/kg/d, 0.2 μmol/kg/d with lung metastatic nodules 7.5 (P < 0.01 compared with the control group), 9.8 (P < 0.05 compared with the control group) and 14.5. And GA-LDV had almost no systemic toxicity in S180 or LLC xenograft models. Conclusion: The newly synthesized GA-LDV derivative demonstrates superior water solubility and significantly enhanced anti-tumor and anti-metastatic activities. The in vitro and in vivo studies indicate that GA-LDV is a promising candidate for further development as a cancer therapeutic agent, with the benefit of potentially reduced systemic toxicity.


  • Open Access

    PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis

    by Yuanyuan Li, Qiqi Feng, Qi Gao, Yaonan Wang, Shurui Zhao, Xiaoyi Zhang, Ming Zhao


  • Open Access

    Poly-α, β-d, l-Aspartyl-Arg-Gly-Asp-Ser-Based Urokinase Nanoparticles for Thrombolysis Therapy

    by Shuangling Chen, Meng Liang, Chengli Wu, Xiaoyi Zhang, Yuji Wang, Ming Zhao

    The most concerning adverse effects of thrombolytic agents are major bleeding and intracranial hemorrhage due to their short half-life, low fibrin specificity, and high dosage. To alleviate bleeding side effects during thrombolytic therapy which would bring about the risk of aggravation, we try to find a novel biodegradable delivery nanosystem to carry drugs to target the thrombus, reduce the dosage of the drug, and system side effects. A novel urokinase/poly-α, β-d, l-aspartyl-Arg-Gly-Asp-Ser complex (UK/PD-RGDS) was synthesized and simply prepared. Its thrombolytic potency was assayed by the bubble-rising method and in vitro thrombolytic activity by the thrombus clot lysis assay separately. The in vivo thrombolytic activity and bleeding complication were evaluated by a rat model of carotid arteriovenous bypass thrombolysis. The thrombolytic potency (1288.19 ± 155.20 U/mg) of the UK/PD-RGDS complex nano-globule (18–130 nm) was 1.3 times that of commercial UK (966.77 ± 148.08 U/mg). In vivo, the UK/PD-RGDS complex (2000 IU/kg) could reduce the dose of UK by 90% while achieving the equivalent thrombolysis effect as the free UK (20,000 IU/kg). Additionally, the UK/PD-RGDS complex decreased the tail bleeding time compared with UK. The organ distribution of the FITC-UK/PD-RGDS complex was explored in the rat model. The UK/PD-RGDS complex could provide a promising platform to enhance thrombolytic efficacy significantly and reduce the major bleeding degree.